NCT03352323已完成3 期
Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Padagis LLC
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Responder
研究概览
简要总结
the study will measure the decrease in redness on the face of rosacea subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-lactating female, 18 years of age or older.
- •Signed informed consent form that meets all criteria of current Food and Drug Administration regulations.
- •Females of childbearing potential must not be pregnant or lactating.
- •Females of childbearing potential must agree to the use of a reliable method of contraception throughout the study.
- •Have clinical diagnosis of rosacea with persistent (non-transient) facial erythema.
- •Have < 3 inflammatory lesions on the face.
- •Have an erythema score of 3 (moderate) or 4 (severe) for both the CEA and the PSA that is reflective of the overall targeted areas.
- •Willing to minimize external factors that might trigger rosacea flare-ups (e.g., spicy foods, hot drinks, hot environments, prolonged sun exposure, strong winds, emotional stress and alcoholic beverages) during the study.
排除标准
- •Forms of rosacea that, in the opinion of the Investigator, would interfere with the diagnosis or assessment of study endpoints
- •Patient has a skin condition that, in the opinion of the Investigator, would interfere with the diagnosis or assessment of rosacea
- •Patients with active sunburn or excessive facial hair such as beards, sideburns, moustaches, etc.
- •Patients with moderate to severe telangiectasial masses
- •History of blood dyscrasia.
- •Significant history or current evidence of any uncontrolled chronic or serious disease or medical condition that would, in the judgment of the Investigator, would put the subject at undue risk or compromise the study assessments.
- •History or current evidence of Raynaud's syndrome, severe, unstable or uncontrolled cardiovascular disease, orthostatic hypotension, uncontrolled hypertension or hypotension, thromboangiitis obliterans, cerebral or coronary insufficiency, renal or hepatic or renal impairment, scleroderma, Sjögren's syndrome, depression, or narrow-angle glaucoma to an extent that, in the opinion of the Investigator, would place the subject at undue risk.
- •Female patients taking hormonal contraceptives or oral estrogen for less than one month or those that plan to change the dosage regimen during the course of the study.
- •Previous participation in this study.
- •Employees of the Investigator or research center or their immediate family members.
- •Inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol.
研究组 & 干预措施
oxymetazoline cream
Experimental
干预措施: Oxymetazoline (Drug)
结局指标
主要结局
Responder
时间窗: Day 15
Responder is defined as a 2-grade improvement from pre-dose on Day 1 on both the Clinician Erythema Assessment and Patient Self Assessment scales
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
The treatment of Rosacea with Oxofulleram. A pilot study to assess the clinical applicability of Oxofullerampapulopustular rosaceaEUCTR2014-004962-76-NLSolenne BV
Unknown
不适用
Demodex Density, Immune Response and Oxidative Stress in Rosacea PatientsRosaceaNCT02556827Istanbul Training and Research Hospital80
已完成
1 期
Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of AcneAcne VulgarisNCT01682200Medivet Pty Ltd50
已完成
不适用
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced ErythemaErythemaSun Damaged SkinSkin InflammationNCT05300542Amazentis SA22
Unknown
2 期
Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical DoxycyclineHivesNCT03968562State University of New York - Downstate Medical Center25